Skip to main content
. Author manuscript; available in PMC: 2022 Mar 2.
Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2020 Sep 6;106:110096. doi: 10.1016/j.pnpbp.2020.110096

Table 8:

Postmortem studies of the CB1/CB2 receptors in mood disorders.

Condition n (cases/controls) Autoradiography 1Antibody mRNA Reference
Dorsolateral prefrontal cortex
Major depressive disorder 26/46 - - ↑CB1
n.s. CB2		 Choi et al., 2012
Major depressive disorder 14/14 - n.s. CB1 - Eggan et al., 2010
Major depressive disorder 10/10 ↑[3H]CP55,940 ↑CB1 (IB) - Hungund et al., 2004
Major depressive disorder 4/4 n.s. [3H]CP55,940 - - Mato et al., 2018
Anterior cingulate cortex
Major depressive disorder 15/15 - ↓CB1 (glia)
n.s. CB1 (neurons)		 - Koethe et al., 2007
Dorsolateral prefrontal cortex
Bipolar disorder 31/46 - - n.s. CB1
n.s. CB2		 Choi et al., 2012
Anterior cingulate cortex
Bipolar disorder 15/15 - n.s. CB1 (glia and neurons) - Koethe et al., 2007

↑: higher; ↓: lower; n.s.: no significant difference from controls; -: no available data;

DLPFC: dorsolateral prefrontal cortex; ACC: anterior cingulate cortex;

[3H]CP55,940: CB1/CB2 receptor agonist; [3H]WIN55212-2: CB1/CB2 receptor agonist.

1

Measured using immunocytochemistry unless noted as immunoblot IB.